S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:HCM

HUTCHMED (HCM) Stock Forecast, Price & News

$9.58
+0.39 (+4.24%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$9.10
$9.90
50-Day Range
$8.91
$20.77
52-Week Range
$8.78
$43.94
Volume
693,662 shs
Average Volume
652,115 shs
Market Capitalization
$1.66 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.12
30 days | 90 days | 365 days | Advanced Chart
Receive HCM News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

HUTCHMED logo

About HUTCHMED

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Headlines

HUTCHMED (NASDAQ:HCM) Trading Up 4.2%
HUTCHMED (NASDAQ:HCM) Shares Gap Up to $10.07
HUTCHMED (NASDAQ:HCM) Sets New 1-Year Low at $13.01
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HCM
Employees
1,759
Year Founded
N/A

Sales & Book Value

Annual Sales
$356.13 million
Book Value
$6.01 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$1.66 billion
Optionable
Not Optionable

Company Calendar

Today
5/22/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

919th out of 1,416 stocks

Pharmaceutical Preparations Industry

459th out of 677 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













HUTCHMED (NASDAQ:HCM) Frequently Asked Questions

Is HUTCHMED a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HUTCHMED in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HUTCHMED stock.
View analyst ratings for HUTCHMED
or view top-rated stocks.

What price target have analysts set for HCM?

4 equities research analysts have issued 12 month price targets for HUTCHMED's stock. Their forecasts range from $45.00 to $52.00. On average, they anticipate HUTCHMED's stock price to reach $47.67 in the next year. This suggests a possible upside of 397.6% from the stock's current price.
View analysts' price targets for HUTCHMED
or view top-rated stocks among Wall Street analysts.

Who are HUTCHMED's key executives?
HUTCHMED's management team includes the following people:
  • Mr. Chi Keung To ACGI, B.Sc., BSc, M.B.A., MBA, Exec. Chairman (Age 70, Pay $85k)
  • Dr. Weiguo Su B.Sc., Ph.D., CEO, Chief Scientific Officer, Exec. VP & Exec. Director (Age 65, Pay $1.36M)
  • Mr. Chig Fung Cheng BEc, CA, CFO & Exec. Director (Age 55, Pay $838.51k)
  • Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, EdM, Solicito, Company Sec. & Non-Exec. Director (Age 70, Pay $74.3k)
  • Dr. Karen Jane Atkin, Exec. VP & COO (Age 56)
  • Mr. Kin Hung Lee M.B.A., Sr. VP of Corp. Fin. & Devel. (Age 45)
  • Mr. Charles George Rupert Nixon, Group Gen. Counsel (Age 52)
  • Ms. Selina Zhang, Sr. VP of Global HR
  • Dr. Qingmei Wang Ph.D., Sr. VP of Bus. Devel. & Strategic Alliances (Age 59)
  • Mr. Hong Chen, Sr. VP & Chief Commercial Officer- China (Age 52)
What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHMED investors own include Telford Homes (TEF), AbbVie (ABBV), Exelixis (EXEL), GW Pharmaceuticals (GWPH), Premier Oil (PMO), CRISPR Therapeutics (CRSP), AT&T (T), Johnson & Johnson (JNJ), NVIDIA (NVDA) and Weyerhaeuser (WY).

When did HUTCHMED IPO?

(HCM) raised $100 million in an initial public offering (IPO) on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities served as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

What is HUTCHMED's stock symbol?

HUTCHMED trades on the NASDAQ under the ticker symbol "HCM."

Who are HUTCHMED's major shareholders?

HUTCHMED's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Capital International Investors (5.27%), Capital Group International Inc. CA (2.42%), Sands Capital Management LLC (2.42%), BlackRock Inc. (2.03%), Bellevue Group AG (1.01%) and Allianz Asset Management GmbH (0.84%).

Which institutional investors are selling HUTCHMED stock?

HCM stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Zeal Asset Management Ltd, JPMorgan Chase & Co., Goldman Sachs Group Inc., Allianz Asset Management GmbH, Sumitomo Mitsui Trust Holdings Inc., State Street Corp, and Sands Capital Management LLC.

Which institutional investors are buying HUTCHMED stock?

HCM stock was purchased by a variety of institutional investors in the last quarter, including Bellevue Group AG, Capital Group International Inc. CA , BlackRock Inc., Bridgewater Associates LP, Qube Research & Technologies Ltd, Mirae Asset Global Investments Co. Ltd., Capital International Investors, and AIA Group Ltd.

How do I buy shares of HUTCHMED?

Shares of HCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is HUTCHMED's stock price today?

One share of HCM stock can currently be purchased for approximately $9.58.

How much money does HUTCHMED make?

HUTCHMED has a market capitalization of $1.66 billion and generates $356.13 million in revenue each year.

How many employees does HUTCHMED have?

HUTCHMED employs 1,759 workers across the globe.

What is HUTCHMED's official website?

The official website for HUTCHMED is www.chi-med.com.

How can I contact HUTCHMED?

HUTCHMED's mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The company can be reached via phone at 852-2121-3888, via email at [email protected], or via fax at 852-2128-1778.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.